Cargando…
Initial Rate of BCR::ABL1 Decline for Response Prediction in Chronic Myeloid Leukemia
Autor principal: | Branford, Susan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Galenos Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421342/ https://www.ncbi.nlm.nih.gov/pubmed/35699277 http://dx.doi.org/10.4274/tjh.galenos.2022.2022.0247 |
Ejemplares similares
-
BCR::ABL1 transcripts and clinical outcome ‐ interrogating the technique
por: Branford, Susan
Publicado: (2022) -
Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
por: Stein, Andrew M, et al.
Publicado: (2013) -
BCR-ABL1 transcript decline ratio combined BCR-ABL1(IS) as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia
por: Cai, Zhimei, et al.
Publicado: (2020) -
Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
por: Polillo, Marialuisa, et al.
Publicado: (2015) -
BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia
por: Pagani, Ilaria S., et al.
Publicado: (2018)